Get the full hip treatment price before you agree

Joint PRP is generally a cash expense

Many health plans don’t pay for PRP placed in a hip. You’ll probably be asked to pay the whole bill. Coverage doesn’t tell you whether your hip will feel better. It tells you who gets charged.

Call both the office and your health plan. Ask whether the exam, X-ray, or any follow-up is billed on its own. When the price would be a hardship, say so before the appointment. Don’t count on a later appeal.

A written total prevents a surprise later

Ask whether the quoted price covers one visit or all planned care. Check the cost of an X-ray, follow-up, and another treatment. If you stop early, find out whether any money comes back. Get each answer in writing.

A success rate needs plain details too. Ask whether success meant less soreness, easier walking, or avoiding surgery, how long the change lasted, and whether the count came from a sound hip study that followed people over time. One person’s good result can’t tell you the odds for your hip.

Ongoing soreness can be discussed before money changes hands

If the hip stays sore after home care, QC Kinetix can examine it and discuss PRP. Staff draw your blood, spin it, collect the platelet-rich liquid, and place it in the hip. The medical provider who examines you can say why it may or may not suit your hip.

The provider can also discuss hip replacement alternatives, meaning care before surgery such as guided exercise, a cane, medicine your doctor allows, or PRP. Here’s what matters: a cash service still needs a clear price and honest limits. You’re free to leave without buying it.

Take the written total home. Compare it with care your plan will cover. Then choose without being rushed.

Sources

1. CMS covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only inside an approved coverage-with-evidence-development clinical research study. There is no national Medicare coverage of PRP for hip osteoarthritis or any other joint condition.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development).. CMS, 2026.

2. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446), and centres claimed a mean clinical efficacy of 82% (SD 9.6%) - a figure with no support in the published evidence. The gap between the quoted number and the trial data is the single most useful thing a patient can be told before a consultation.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. The journal of knee surgery, 2018. DOI: 10.1055/s-0037-1604443.

3. Pooled analysis of national joint registries (Australia and Finland, 215,676 hip replacements) put 25-year all-cause construct survival at 57.9% (95% CI 57.1-58.7); pooled case series gave 77.6% (95% CI 76.0-79.2). The authors conclude patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

   Evans JT, et al. — How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up.. The Lancet, 2019. DOI: 10.1016/S0140-6736(18)31665-9.

4. A 2016 analysis of internet marketing found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the United States - not only in countries with lax regulation - and concluded that regulators must better oversee this marketplace.

   Turner L, Knoepfler P — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.